Company: JUPGF
Filing Date: 2025-09-25
Form Type: F-1/A
Source: 0001493152-25-014979
Chunk: 163

Company: ATLAS CRITICAL MINERALS Corp
Filing Date: 2025-09-25
Form: F-1/A
Chunk 163
---
 exhibit to the registration
statement of which this prospectus is part. Each underwriter reserves the right to withdraw, cancel or modify offers to the public and
to reject orders in whole or in part.

Bradesco Securities, Inc.
will act as agent of Banco Bradesco BBI S.A. for sales of our Common Shares in the United States of America. Banco Bradesco BBI S.A.
is not a broker-dealer registered with the SEC, and therefore may not make any sales of our Common Shares in the United States to U.S.
persons. Banco Bradesco BBI S.A. and Bradesco Securities, Inc. are affiliates of Banco Bradesco S.A.

Over-Allotment Option

We have granted to the
underwriters an option, exercisable no later than 45 calendar days after the date of the underwriting agreement, to purchase up to 120,000
additional shares of common stock (an amount equal to 15% of the shares sold in the offering, assuming a total of 800,000 shares of common stock are sold at the underwritten offering price per share of $10.00 (the midpoint of the $9.00 to $11.00 estimated price range of the underwritten offering price)), less underwriting discounts and commissions. The underwriters may exercise this option only to cover over-allotments, if any, made in connection with this offering. To the extent the option is exercised and the conditions of the underwriting agreement are satisfied, we will be obligated to sell to the underwriters, and the underwriters will be obligated to purchase, these additional shares of common stock. The underwriters will offer these additional shares of common stock on the same terms as those on which the other shares of common stock are being offered hereby.

Discounts, Commissions, and Representative’s Warrants

We have agreed to sell
the common stock to the underwriters at a discount equal to seven percent (7.0%) of the aggregate gross proceeds raised in this offering.
We have also agreed to (i) grant to the Representative warrants to purchase a number of shares equal to six percent (6.0%) of the total
number of shares of common stock sold in this offering at an exercise price equal to 115% of the underwritten offering price in this
offering. The Representative’s Warrants will be non-exercisable for six months after the date of the commencement of sales in this
offering, and will expire five (5